We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals

160 hedge funds and large institutions have $1.82B invested in Mirum Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 65 increasing their positions, 49 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more funds holding in top 10

Funds holding in top 10: 49 (+5)

49% more call options, than puts

Call options by funds: $3.64M | Put options by funds: $2.44M

36% more capital invested

Capital invested by funds: $1.34B → $1.82B (+$486M)

33% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 49

1% less ownership

Funds ownership: 114.24%113.24% (-1%)

7% less funds holding

Funds holding: 172160 (-12)

31% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 36

Holders
160
Holders Change
-12
Holders Change %
-6.98%
% of All Funds
2.31%
Holding in Top 10
9
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+125%
% of All Funds
0.13%
New
25
Increased
65
Reduced
49
Closed
36
Calls
$3.64M
Puts
$2.44M
Net Calls
+$1.2M
Net Calls Change
+$1.34M
Name Holding Trade Value Shares
Change
Change in
Stake
FLSM
1
Frazier Life Sciences Management
California
$222M
Janus Henderson Group
2
Janus Henderson Group
United Kingdom
$171M +$58.2M +2,221,537 +80%
BI
3
BVF Inc
California
$149M
EAM
4
Eventide Asset Management
Massachusetts
$124M +$8.24M +314,420 +10%
BlackRock
5
BlackRock
New York
$111M +$20.6M +785,776 +32%
Vanguard Group
6
Vanguard Group
Pennsylvania
$83.7M +$6.16M +235,048 +11%
RSCM
7
Rock Springs Capital Management
Maryland
$60.6M -$2.22M -84,526 -5%
Citadel Advisors
8
Citadel Advisors
Florida
$54.2M +$5.06M +193,118 +14%
NHAS
9
Novo Holdings A/S
Denmark
$51.3M
State Street
10
State Street
Massachusetts
$51.2M -$34.8M -1,326,255 -47%
TCM
11
Tang Capital Management
California
$44M +$2.62M +100,000 +8%
CCM
12
Cadian Capital Management
New York
$42.2M -$27.7M -1,057,446 -46%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$41M -$10.4M -398,286 -25%
Franklin Resources
14
Franklin Resources
California
$32.2M +$5.14K +196 +0%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$31M +$5.51M +210,041 +30%
Pictet Asset Management
16
Pictet Asset Management
Switzerland
$29.9M -$2.12M -80,801 -8%
Goldman Sachs
17
Goldman Sachs
New York
$26M +$1.54M +58,902 +8%
PCH
18
Polar Capital Holdings
United Kingdom
$25.3M +$3.04M +116,049 +19%
APM
19
Avidity Partners Management
Texas
$25M -$10.8M -411,746 -36%
FTM
20
First Turn Management
California
$24M -$6.69M -255,256 -27%
ClearBridge Investments
21
ClearBridge Investments
New York
$23.9M +$11.4M +436,349 +166%
William Blair Investment Management
22
William Blair Investment Management
Illinois
$23.2M +$1.33M +50,667 +8%
Morgan Stanley
23
Morgan Stanley
New York
$18.5M +$4.89M +186,434 +53%
BCM
24
Boone Capital Management
Georgia
$17.9M +$1.88M +71,781 +16%
CS
25
Candriam SCA
Luxembourg
$17.4M +$13.3M +508,475 New

MIRM Hedge Fund Activity: Q2 2024 in Review

160 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q2 2024, worth a combined $1.82B — up 36% from $1.34B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of MIRM and 25 opened new positions — a net loss of 11 holders — while 49 trimmed existing stakes and 65 added.

The largest buyer was Janus Henderson Group, adding an estimated $58.2M. The largest seller was State Street, cutting an estimated $34.8M.

  • 160 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q2 2024, down from 172 in Q1 2024.
  • Funds reported $1.82B of Mirum Pharmaceuticals stock for Q2 2024, up 36% quarter-over-quarter.
  • 25 funds opened new Mirum Pharmaceuticals positions in Q2 2024 and 36 closed out, a net change of -11 holders.
  • The largest Mirum Pharmaceuticals buyer in Q2 2024 was Janus Henderson Group, an estimated $58.2M added.
  • The largest Mirum Pharmaceuticals seller in Q2 2024 was State Street, an estimated $34.8M sold.

Based on aggregated 13F filings for Q2 2024.